Cumberland Pharmaceuticals Inc.
|$114 M||Market Cap|
|N/A||EBIT / EV|
|N/A||FCF / EV|
|1.5%||3yr Avg Revenue Growth|
Business Model Diligence
We do not yet have Business Model Diligence for this stock.
|Cannot calculate EBIT / Enterprise Value, company has negative EBIT.|
|Cannot calculate Free Cash Flow / Enterprise Value, company has negative Free Cash Flow.|
|Cannot calculate Return on Invested Capital, company has negative EBIT.|
|Cannot calculate Cash Return on Invested Capital, company has negative Free Cash Flow.|
|The 3 Year Average Revenue Growth Value of 1.5% ranks as Average.|
|Near-term Financial Health appears to be Very Good. The Current Ratio is 4.18.|
Cumberland Pharmaceuticals, Inc. engages in the acquisition, development, and commercialization of branded prescription products. Its product brands include Acetadote, Caldolor, Kristalose, Omeclamox-Pak, Vaprisol, and Ethyol. The company was founded by A. J. Kazimi on January 6, 1999 and is headquartered in Nashville, TN.
|Cognex Corporation (CGNX)|
|iRobot Corporation (IRBT)|
|Target Corporation (TGT)|
|Buckle, Inc. (BKE)|
|Talend SA Sponsored ADR (TLND)|